The increased passive stake signals continued institutional confidence but does not imply activist intent. Monitor for any future conversion to a 13D filing, which would indicate a shift to active engagement.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $63.89entry
- T+1 · 8d ago +5.70%α +3.33% · $67.53
- T+5 · 4d ago −0.81%α −3.41% · $63.37
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing an 11.6% passive stake in Vaxcyte as of October 31, 2026, up from 9.6% in the prior filing. The increase reflects continued accumulation by a major institutional holder following positive Phase 3 data for VAX-31 and a recent $1.1B capital raise.
Key Financial Metrics
Key Facts
- T. Rowe Price Investment Management disclosed beneficial ownership of 18,136,166 shares of Vaxcyte common stock as of October 31, 2026.
- The stake represents 11.6% of shares outstanding, up from 9.6% in the prior filing.
- The filing is a passive investor update under Rule 13d-1(b); the investor certifies shares were not acquired to influence control.
- T. Rowe Price Capital Appreciation Fund holds 7,430,887 shares (5.2% of class) within the total.
Financial Impact
Stake increased by approximately 2.0 percentage points; no transaction values disclosed.
Risk Factors
- As a passive filer, T. Rowe Price could reduce the stake without public notice until the next 13G amendment threshold is crossed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001897612-26-000705 |
| Document: 0001897612-26-000705-index.html | 0001897612-26-000705 |
| Document: 0001897612-26-000705.txt | 0001897612-26-000705 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Viewing Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers